Sarcoma  >>  Neulasta (pegfilgrastim)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Neulasta (pegfilgrastim) / Roche
NCT00061984: Doxorubicin With or Without Ifosfamide and Pegfilgrastim in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma

Completed
3
455
Canada, Europe
pegfilgrastim, doxorubicin hydrochloride, ifosfamide, multimodality therapy
European Organisation for Research and Treatment of Cancer - EORTC
Sarcoma
05/10
07/12
NCT01012297: Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma

Terminated
3
107
US
Bevacizumab, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF rhuMAb, Avastin, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, Docetaxel, RP56976, Taxotere, Taxotere Injection Concentrate, Filgrastim, Filgrastim XM02, G-CSF, Neupogen, r-metHuG-CSF, Recombinant Methionyl Human Granulocyte Colony Stimulating Factor, rG-CSF, Tbo-filgrastim, Tevagrastim, Gemcitabine Hydrochloride, dFdCyd, Difluorodeoxycytidine Hydrochloride, Gemzar, LY-188011, Pegfilgrastim, Filgrastim SD-01, filgrastim-SD/01, Neulasta, SD-01, SD-01 sustained duration G-CSF, Placebo, placebo therapy, PLCB, sham therapy
National Cancer Institute (NCI), NRG Oncology
Recurrent Uterine Corpus Sarcoma, Stage IIIA Uterine Sarcoma, Stage IIIB Uterine Sarcoma, Stage IIIC Uterine Sarcoma, Stage IVA Uterine Sarcoma, Stage IVB Uterine Sarcoma, Uterine Corpus Leiomyosarcoma
09/15
09/15
NCT01933932 / 2013-001676-38: Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC

Checkmark SELECT-1 (selumetinib + docetaxel combo) trial for KRAS-mutant NSCLC
Aug 2016 - Aug 2016: SELECT-1 (selumetinib + docetaxel combo) trial for KRAS-mutant NSCLC
Checkmark Enrollment completion in P3 SELECT-1 trial in 2L KRASm NSCLC
Jan 2016 - Jan 2016: Enrollment completion in P3 SELECT-1 trial in 2L KRASm NSCLC
Checkmark Pivotal trial initiation in 2nd-line KRASm NSCLC
More
Active, not recruiting
3
510
Europe, Canada, US, RoW
Selumetinib, AZD6244; ARRY-142886, Docetaxel, Placebo, Pegylated G-CSF, Pegfilgrastim 6 mg
AstraZeneca
Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV
06/16
12/24
GOG study , NCT01533207: Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery

Terminated
3
38
Europe, US, RoW
Clinical Observation, observation, Docetaxel, Docecad, RP56976, Taxotere, Taxotere Injection Concentrate, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, hydroxydaunorubicin, Rubex, Filgrastim, FILGRASTIM, LICENSE HOLDER UNSPECIFIED, G-CSF, Neupogen, r-metHuG-CSF, Recombinant Methionyl Human Granulocyte Colony Stimulating Factor, rG-CSF, Tevagrastim, Gemcitabine Hydrochloride, dFdCyd, Difluorodeoxycytidine Hydrochloride, Gemzar, LY-188011, LY188011, Pegfilgrastim, Filgrastim SD-01, filgrastim-SD/01, Fulphila, HSP-130, Jinyouli, Neulasta, Neulastim, Pegfilgrastim Biosimilar HSP-130, SD-01, SD-01 sustained duration G-CSF
Gynecologic Oncology Group, National Cancer Institute (NCI)
Stage I Uterine Sarcoma AJCC v7, Uterine Corpus Leiomyosarcoma
06/18
02/19

Download Options